Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2019-01-28 Tx date 2019-01-23 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
-150,000 vol |
0 | |
Filed 2018-12-18 Tx date 2018-11-22 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+150,000 vol |
150,000 | |
Filed 2018-12-18 Tx date 2018-10-01 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-26 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-26 Tx date 2018-11-22 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$13,500
+150,000 vol $0.09 each |
150,000 | |
Filed 2018-10-23 Tx date 2018-09-28 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$13,500
+100,000 vol $0.135 each |
100,000 | |
Filed 2018-10-23 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-10-23 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-10-23 Tx date 2018-06-21 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,500
+100,000 vol $0.185 each |
100,000 | |
Filed 2018-09-19 Tx date 2018-09-17 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-30,000
-200,000 vol $0.15 each |
-65,000 | |
Filed 2018-09-19 Tx date 2018-09-17 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
$30,000
+200,000 vol $0.15 each |
135,000 | |
Filed 2018-08-10 Tx date 2018-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$684,336
+4,677,625 vol $0.1463 each |
12,668,322 | |
Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-03 Tx date 2018-08-01 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-35,400
-236,000 vol $0.15 each |
1,307,250 | |
Filed 2018-06-27 Tx date 2018-06-26 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$545,376
+4,277,465 vol $0.1275 each |
14,570,776 | |
Filed 2018-06-27 Tx date 2018-06-26 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$146,200
+1,000,000 vol $0.1462 each |
10,293,311 | |
Filed 2018-06-21 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-170,000
-1,000,000 vol $0.17 each |
9,293,311 | |
Filed 2018-06-21 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-500,000 vol |
10,293,311 | |
Filed 2018-06-21 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-1,500,000 vol |
||
Filed 2018-06-19 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-1,500,000 vol |
9,293,311 | |
Filed 2018-03-15 Tx date 2018-03-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$810,000
+3,000,000 vol $0.27 each |
10,793,311 | |
Filed 2018-03-14 Tx date 2018-03-12 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$7,874
+29,166 vol $0.27 each |
160,970 | |
Filed 2018-03-14 Tx date 2018-03-12 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$810,000
+3,000,000 vol $0.27 each |
7,990,697 | |
Filed 2018-03-02 Tx date 2018-02-27 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-3,500,000 vol |
4,990,697 | |
Filed 2018-02-14 Tx date 2018-02-13 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$1,181,250
+4,500,000 vol $0.2625 each |
5,587,488 | |
Filed 2018-02-14 Tx date 2018-02-13 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,706,250
+6,500,000 vol $0.2625 each |
8,490,697 | |
Filed 2018-01-22 Tx date 2018-01-19 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-53,100
-90,000 vol $0.59 each |
476,500 | |
Filed 2018-01-22 Tx date 2018-01-18 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-53,100
-90,000 vol $0.59 each |
566,500 | |
Filed 2018-01-18 Tx date 2018-01-16 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,750
-25,000 vol $0.67 each |
656,500 | |
Filed 2018-01-18 Tx date 2018-01-16 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-43,771
-65,000 vol $0.67 each |
681,500 | |
Filed 2018-01-17 Tx date 2018-01-16 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$122,743
+762,379 vol $0.161 each |
7,793,311 | |
Filed 2018-01-16 Tx date 2018-01-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-47,700
-90,000 vol $0.53 each |
836,500 | |
Filed 2018-01-16 Tx date 2018-01-15 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-53,100
-90,000 vol $0.59 each |
746,500 | |
Filed 2018-01-16 Tx date 2018-01-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-48,042
-90,000 vol $0.53 each |
926,500 | |
Filed 2018-01-16 Tx date 2018-01-11 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,300
-30,000 vol $0.61 each |
1,016,500 | |
Filed 2018-01-16 Tx date 2018-01-11 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-36,000
-60,000 vol $0.60 each |
1,046,500 | |
Filed 2018-01-08 Tx date 2018-01-05 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,060
-4,500 vol $0.68 each |
1,106,500 | |
Filed 2018-01-08 Tx date 2018-01-05 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-57,652.65
-85,500 vol $0.67 each |
1,111,000 | |
Filed 2018-01-08 Tx date 2018-01-04 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-64,800
-90,000 vol $0.72 each |
1,196,500 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-31,500
-50,000 vol $0.63 each |
42,971 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,500
-50,000 vol $0.61 each |
92,971 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-29,500
-50,000 vol $0.59 each |
142,971 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,500
-50,000 vol $0.57 each |
192,971 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-168,000
-300,000 vol $0.56 each |
242,971 | |
Filed 2018-01-03 Tx date 2018-01-02 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,500
-50,000 vol $0.55 each |
542,971 | |
Filed 2018-01-02 Tx date 2017-12-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,575
-26,500 vol $0.55 each |
592,971 | |
Filed 2017-12-21 Tx date 2017-12-20 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Indirect Ownership)
|
Options
51 - Exercise of options
|
-133,333 vol |
66,667 | |
Filed 2017-12-21 Tx date 2017-12-20 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Indirect Ownership)
|
Common Shares
51 - Exercise of options
|
$19,333
+133,333 vol $0.145 each |
535,889 | |
Filed 2017-12-20 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$20,999
+48,837 vol $0.43 each |
619,471 | |
Filed 2017-12-20 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$15,749
+36,627 vol $0.43 each |
7,030,932 | |
Filed 2017-12-20 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$6,299
+14,651 vol $0.43 each |
131,804 | |
Filed 2017-12-20 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$15,350
+35,698 vol $0.43 each |
1,990,697 | |
Filed 2017-12-19 Tx date 2017-12-15 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-55,000
-100,000 vol $0.55 each |
402,556 | |
Filed 2017-12-19 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-200,000 vol |
135,000 | |
Filed 2017-12-19 Tx date 2017-12-18 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
+200,000 vol |
335,000 | |
Filed 2017-12-18 Tx date 2017-12-15 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-33,000
-50,000 vol $0.66 each |
570,634 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,427.50
-40,500 vol $0.455 each |
620,634 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,250
-50,000 vol $0.305 each |
661,134 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-24,500
-50,000 vol $0.49 each |
711,134 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,500
-50,000 vol $0.47 each |
761,134 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,370
-9,500 vol $0.46 each |
811,134 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,500
-50,000 vol $0.33 each |
820,634 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,800
-40,000 vol $0.32 each |
870,634 | |
Filed 2017-12-18 Tx date 2017-12-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,750
-50,000 vol $0.315 each |
910,634 | |
Filed 2017-12-15 Tx date 2017-12-13 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-70,000
-100,000 vol $0.70 each |
1,543,250 | |
Filed 2017-12-15 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-20,500
-50,000 vol $0.41 each |
1,643,250 | |
Filed 2017-12-15 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,000
-50,000 vol $0.46 each |
1,693,250 | |
Filed 2017-12-13 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,360
-66,000 vol $0.46 each |
1,087,488 | |
Filed 2017-12-13 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-48,000
-100,000 vol $0.48 each |
1,286,500 | |
Filed 2017-12-13 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,000
-50,000 vol $0.54 each |
1,386,500 | |
Filed 2017-12-13 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-50,000
-100,000 vol $0.50 each |
1,436,500 | |
Filed 2017-12-06 Tx date 2017-12-06 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-1,046,667 vol |
6,994,305 | |
Filed 2017-11-29 Tx date 2017-11-28 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,200
-10,000 vol $0.32 each |
960,634 | |
Filed 2017-11-29 Tx date 2017-11-28 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,750
-50,000 vol $0.315 each |
970,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,000
-50,000 vol $0.28 each |
1,020,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-24,500
-100,000 vol $0.245 each |
1,070,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,500
-50,000 vol $0.29 each |
1,170,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,250
-50,000 vol $0.285 each |
1,220,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-13,750
-50,000 vol $0.275 each |
1,270,634 | |
Filed 2017-11-29 Tx date 2017-11-27 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-13,250
-50,000 vol $0.265 each |
1,320,634 | |
Filed 2017-11-27 Tx date 2017-11-24 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,500
-50,000 vol $0.23 each |
1,370,634 | |
Filed 2017-11-27 Tx date 2017-11-24 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,250
-50,000 vol $0.225 each |
1,420,634 | |
Filed 2017-11-27 Tx date 2017-11-23 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,250
-50,000 vol $0.225 each |
1,470,634 | |
Filed 2017-11-27 Tx date 2017-11-22 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-5,405
-23,500 vol $0.23 each |
1,520,634 | |
Filed 2017-11-27 Tx date 2017-11-22 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-22,500
-100,000 vol $0.225 each |
1,544,134 | |
Filed 2017-11-27 Tx date 2017-11-22 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,500
-50,000 vol $0.23 each |
1,644,134 | |
Filed 2017-11-08 Tx date 2017-11-06 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,275
-107,500 vol $0.17 each |
1,743,250 | |
Filed 2017-11-01 Tx date 2017-10-30 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$7,352
+52,972 vol $0.1388 each |
1,694,134 | |
Filed 2017-11-01 Tx date 2017-10-30 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$3,151
+22,702 vol $0.1388 each |
117,153 | |
Filed 2017-11-01 Tx date 2017-10-30 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$7,788
+56,116 vol $0.1388 each |
1,954,999 | |
Filed 2017-11-01 Tx date 2017-10-03 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-27,586 vol |
1,898,883 | |
Filed 2017-10-31 Tx date 2017-10-30 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$13,745
+99,099 vol $0.1387 each |
8,040,972 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
Filed 2017-09-12 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-08 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,504
+96,551 vol $0.1088 each |
1,641,162 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
Filed 2017-09-12 Tx date 2016-11-02 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
Filed 2017-09-12 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-11 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,750
-45,000 vol $0.15 each |
36,159 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
Filed 2017-09-12 Tx date 2017-05-29 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-11 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
$145,000
+1,000,000 vol $0.145 each |
2,885,000 | |
Filed 2017-09-12 Tx date 2017-09-11 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,247
+48,275 vol $0.1087 each |
7,941,873 | |
Filed 2017-09-12 Tx date 2017-09-11 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$14,499
+100,000 vol $0.145 each |
7,893,598 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
25,000 | |
Filed 2017-09-12 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-08 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$3,151
+28,965 vol $0.1088 each |
94,451 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+1,000,000 vol |
1,000,000 | |
Filed 2017-09-12 Tx date 2017-04-10 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-08 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$15,757
+144,827 vol $0.1088 each |
1,926,469 | |
Filed 2017-08-30 Tx date 2017-08-24 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-200,000 vol |
7,793,598 | |
Filed 2017-08-30 Tx date 2017-08-24 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$23,000
+200,000 vol $0.115 each |
7,993,598 | |
Filed 2017-08-30 Tx date 2017-08-24 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,246
+60,869 vol $0.0862 each |
7,793,598 | |
Filed 2017-08-23 Tx date 2017-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,493
+121,739 vol $0.0862 each |
1,544,611 | |
Filed 2017-08-23 Tx date 2017-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$6,995
+81,159 vol $0.0862 each |
81,159 | |
Filed 2017-08-23 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-08-23 Tx date 2017-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$3,148
+36,521 vol $0.0862 each |
65,486 | |
Filed 2017-08-23 Tx date 2017-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$13,358
+154,968 vol $0.0862 each |
1,781,642 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$36,250
+250,000 vol $0.145 each |
1,422,872 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,504
+96,551 vol $0.1088 each |
1,172,872 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,247
+48,275 vol $0.1087 each |
7,732,729 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$72,500
+500,000 vol $0.145 each |
7,684,454 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$3,151
+28,965 vol $0.1088 each |
28,965 | |
Filed 2017-07-17 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Boddy, Christina Lynn
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$72,500
+500,000 vol $0.145 each |
1,626,674 | |
Filed 2017-07-17 Tx date 2017-07-12 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$13,506
+124,137 vol $0.1088 each |
1,126,674 | |
Filed 2017-06-21 Tx date 2017-06-15 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-48,000
-300,000 vol $0.16 each |
1,850,750 | |
Filed 2017-06-21 Tx date 2017-06-16 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Control or Direction)
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
502,556 | |
Filed 2017-06-21 Tx date 2017-05-29 |
$ATT
Abattis Bioceuticals Corp. |
Gordon, Peter Vicars
4 - Director of Issuer
Holder: P V Gordon Holdings Ltd. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
2,556 | ||
Filed 2017-06-17 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-92,500
-500,000 vol $0.185 each |
7,184,454 | |
Filed 2017-06-17 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
7,684,454 | |
Filed 2017-06-15 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
2,150,750 | |
Filed 2017-06-15 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,247
+37,837 vol $0.1387 each |
7,184,454 | |
Filed 2017-06-15 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
1,002,537 | |
Filed 2017-06-15 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,443
+75,675 vol $0.138 each |
502,537 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$46,250
+250,000 vol $0.185 each |
1,076,321 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,503
+75,675 vol $0.1388 each |
826,321 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
1,536,500 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
1,650,750 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
||
Filed 2017-06-06 Tx date 2017-04-28 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$15,750
+87,500 vol $0.18 each |
426,862 | |
Filed 2017-05-25 Tx date 2017-05-19 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-20,500
-100,000 vol $0.205 each |
169,191 | |
Filed 2017-05-12 Tx date 2017-05-08 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,960
-68,000 vol $0.22 each |
269,191 | |
Filed 2017-05-12 Tx date 2017-05-08 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,560
-72,000 vol $0.23 each |
337,191 | |
Filed 2017-05-05 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-18,000
-300,000 vol $0.06 each |
150,000 | |
Filed 2017-05-05 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$18,000
+300,000 vol $0.06 each |
409,191 | |
Filed 2017-05-04 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,500
-100,000 vol $0.235 each |
109,191 | |
Filed 2017-05-04 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,140
-100,000 vol $0.2314 each |
209,191 | |
Filed 2017-05-04 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,750
-50,000 vol $0.255 each |
309,191 | |
Filed 2017-05-04 Tx date 2017-05-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,500
-50,000 vol $0.25 each |
359,191 | |
Filed 2017-04-26 Tx date 2017-04-20 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,230
-100,000 vol $0.2723 each |
409,191 | |
Filed 2017-04-26 Tx date 2017-04-06 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-5,125
-25,000 vol $0.205 each |
509,191 | |
Filed 2017-04-26 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,750
-150,000 vol $0.205 each |
534,191 | |
Filed 2017-04-26 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,375
-75,000 vol $0.205 each |
684,191 | |
Filed 2017-04-26 Tx date 2017-04-04 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-10,250
-50,000 vol $0.205 each |
759,191 | |
Filed 2017-04-26 Tx date 2017-04-04 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-10,370
-50,000 vol $0.2074 each |
809,191 | |
Filed 2017-04-26 Tx date 2017-04-04 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-86.00
-430 vol $0.20 each |
859,191 | |
Filed 2017-04-26 Tx date 2017-04-03 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,500
-50,000 vol $0.17 each |
859,621 | |
Filed 2017-04-26 Tx date 2017-04-03 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,862.50
-73,500 vol $0.175 each |
909,621 | |
Filed 2017-04-26 Tx date 2017-04-03 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,250
-50,000 vol $0.185 each |
983,121 | |
Filed 2017-04-26 Tx date 2017-04-03 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,770
-26,500 vol $0.18 each |
1,033,121 | |
Filed 2017-04-25 Tx date 2012-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+50,000 vol |
||
Filed 2017-04-25 Tx date 2012-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+50,000 vol |
||
Filed 2017-04-25 Tx date 2017-04-20 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-65,000 vol |
135,000 | |
Filed 2017-04-25 Tx date 2015-03-11 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
+200,000 vol |
200,000 | |
Filed 2017-04-25 Tx date 2017-04-20 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$117,966
+669,504 vol $0.1762 each |
7,146,617 | |
Filed 2017-04-25 Tx date 2015-03-17 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$26,000
+200,000 vol $0.13 each |
1,053,488 | |
Filed 2017-04-25 Tx date 2017-04-20 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
+339,362 vol |
339,362 | |
Filed 2017-04-25 Tx date 2017-04-10 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-04-17 Tx date 2017-04-13 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-21,315
-73,500 vol $0.29 each |
1,036,500 | |
Filed 2017-04-16 Tx date 2017-04-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$80,250
+535,000 vol $0.15 each |
6,477,113 | |
Filed 2017-04-15 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$93,000
+600,000 vol $0.155 each |
1,150,750 | |
Filed 2017-04-15 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
||
Filed 2017-04-15 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,675
-45,000 vol $0.215 each |
705,750 | |
Filed 2017-04-15 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,450
-45,000 vol $0.21 each |
||
Filed 2017-04-10 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
680,646 | |
Filed 2017-04-10 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
1,110,000 | |
Filed 2017-04-10 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
1,050,750 | |
Filed 2017-04-10 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Control or Direction)
|
Common Shares
46 - Compensation for services
|
$10,500
+70,000 vol $0.15 each |
750,646 | |
Filed 2017-04-05 Tx date 2012-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$20,000
+250,000 vol $0.08 each |
300,000 | |
Filed 2017-04-03 Tx date 2017-03-31 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-31,000
-155,000 vol $0.20 each |
550,750 | |
Filed 2017-04-03 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,450
-45,000 vol $0.21 each |
705,750 | |
Filed 2017-04-03 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,900
-60,000 vol $0.115 each |
750,750 | |
Filed 2017-04-03 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$90,000
+750,000 vol $0.12 each |
1,059,621 | |
Filed 2017-03-31 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-17,550
-90,000 vol $0.195 each |
610,000 | |
Filed 2017-03-28 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$90,000
+750,000 vol $0.12 each |
868,400 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$60,000
+500,000 vol $0.12 each |
700,000 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,300
-60,000 vol $0.155 each |
60,750 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$90,000
+750,000 vol $0.12 each |
810,750 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$60,000
+500,000 vol $0.12 each |
892,687 | |
Filed 2017-03-15 Tx date 2017-03-10 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Options
51 - Exercise of options
|
$42,000
+700,000 vol $0.06 each |
1,750,000 | |
Filed 2017-03-15 Tx date 2017-03-10 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Options
51 - Exercise of options
|
$-42,000
-700,000 vol $0.06 each |
1,050,000 | |
Filed 2017-03-15 Tx date 2017-03-13 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$10,504
+90,322 vol $0.1163 each |
5,942,113 | |
Filed 2017-03-15 Tx date 2017-03-10 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-13,175
-85,000 vol $0.155 each |
5,851,791 | |
Filed 2017-03-15 Tx date 2017-03-10 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,000
-200,000 vol $0.15 each |
5,936,791 | |
Filed 2017-03-14 Tx date 2017-03-13 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$21,009
+180,646 vol $0.1163 each |
180,646 | |
Filed 2017-03-14 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Holder: Efilcon Consulting Tech Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-03-06 Tx date 2017-03-03 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,021.325
-157,705 vol $0.165 each |
392,687 | |
Filed 2017-01-27 Tx date 2017-01-18 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+200,000 vol |
200,000 | |
Filed 2017-01-27 Tx date 2017-01-18 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-14,000
-200,000 vol $0.07 each |
0 | |
Filed 2017-01-27 Tx date 2016-11-02 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Warrants
99 - Correction of information
|
+200,000 vol |
400,000 | |
Filed 2017-01-27 Tx date 2017-01-18 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$40,000,000,000
+200,000 vol $200,000 each |
200,000 | |
Filed 2017-01-26 Tx date 2017-01-23 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Warrants
54 - Exercise of warrants
|
$21,000
+300,000 vol $0.07 each |
555,556 | |
Filed 2017-01-26 Tx date 2017-01-23 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Warrants
54 - Exercise of warrants
|
$-21,000
-300,000 vol $0.07 each |
255,556 | |
Filed 2017-01-26 Tx date 2017-01-23 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,237
+51,852 vol $0.101 each |
6,136,791 | |
Filed 2017-01-23 Tx date 2017-01-17 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$10,505
+103,704 vol $0.1013 each |
550,392 | |
Filed 2017-01-18 Tx date 2017-01-09 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,000
-200,000 vol $0.14 each |
0 | |
Filed 2017-01-16 Tx date 2017-01-13 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,520
-18,000 vol $0.14 each |
446,688 | |
Filed 2017-01-15 Tx date 2017-01-09 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
+200,000 vol |
0 | |
Filed 2017-01-15 Tx date 2017-01-09 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-200,000 vol |
-200,000 | |
Filed 2017-01-15 Tx date 2017-01-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,000
-200,000 vol $0.14 each |
953,488 | |
Filed 2017-01-15 Tx date 2017-01-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$18,000
+200,000 vol $0.09 each |
1,153,488 | |
Filed 2017-01-12 Tx date 2017-01-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,100
-165,000 vol $0.14 each |
464,688 | |
Filed 2017-01-09 Tx date 2016-08-02 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
36 - Conversion or exchange
|
$46,259
+925,186 vol $0.05 each |
4,987,343 | |
Filed 2016-12-22 Tx date 2016-12-19 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,450
-123,000 vol $0.15 each |
120,750 | |
Filed 2016-12-19 Tx date 2016-12-12 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,249
+53,846 vol $0.0975 each |
5,159,753 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$5,813
+59,621 vol $0.0975 each |
309,621 | |
Filed 2016-12-14 Tx date 2016-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$5,249
+53,846 vol $0.0975 each |
629,688 | |
Filed 2016-12-04 Tx date 2016-11-25 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,500
-100,000 vol $0.145 each |
200,000 | |
Filed 2016-11-22 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$5,250
+43,750 vol $0.12 each |
575,842 | |
Filed 2016-11-22 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Xie, Shuang
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
532,092 | ||
Filed 2016-11-18 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$5,250
+43,750 vol $0.12 each |
5,105,907 | |
Filed 2016-11-17 Tx date 2016-11-15 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$14,000
+200,000 vol $0.07 each |
300,000 | |
Filed 2016-11-17 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+100,000 vol |
100,000 | |
Filed 2016-11-17 Tx date 2016-11-02 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-11-17 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+43,750 vol |
243,750 | |
Filed 2016-11-17 Tx date 2016-11-15 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-14,000
-200,000 vol $0.07 each |
0 | |
Filed 2016-11-07 Tx date 2016-11-02 |
$ATT
Abattis Bioceuticals Corp. |
Panenka, William
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$45,000
+250,000 vol $0.18 each |
925,000 | |
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$45,000
+250,000 vol $0.18 each |
250,000 | |
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
+1,750,000 vol |
1,750,000 | |
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$117,800
+950,000 vol $0.124 each |
5,062,157 | |
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$3,100
+25,000 vol $0.124 each |
4,112,157 | |
Filed 2016-10-24 Tx date 2016-09-20 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,405
+25,000 vol $0.0562 each |
4,087,157 | |
Filed 2016-10-24 Tx date 2016-08-02 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$61,019
+1,220,391 vol $0.05 each |
4,062,157 | |
Filed 2016-10-24 Tx date 2016-07-31 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$875.00
+25,000 vol $0.035 each |
2,841,766 | |
Filed 2016-10-24 Tx date 2016-06-30 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$875.00
+25,000 vol $0.035 each |
2,816,766 | |
Filed 2016-10-24 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-25 Tx date 2016-06-30 |
$ATT
Abattis Bioceuticals Corp. |
Yung, Michael David
5 - Senior Officer of Issuer
Holder: 1072915 BC LTD (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,416
+135,417 vol $0.04 each |
545,337 | |
Filed 2016-06-15 Tx date 2016-06-15 |
$ATT
Abattis Bioceuticals Corp. |
Yung, Michael David
5 - Senior Officer of Issuer
Holder: 1072915 BC LTD (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,416
+108,333 vol $0.05 each |
409,920 | |
Filed 2016-06-06 Tx date 2016-05-24 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,500
+100,000 vol $0.045 each |
953,488 | |
Filed 2016-06-01 Tx date 2016-05-31 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,250
+25,000 vol $0.05 each |
2,791,766 | |
Filed 2016-05-31 Tx date 2016-05-31 |
$ATT
Abattis Bioceuticals Corp. |
Amin Shanjani, Maryam
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$500.00
+10,000 vol $0.05 each |
280,000 | |
Filed 2016-05-27 Tx date 2016-05-19 |
$ATT
Abattis Bioceuticals Corp. |
Amin Shanjani, Maryam
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
270,000 | ||
Filed 2016-05-09 Tx date 2016-05-03 |
$ATT
Abattis Bioceuticals Corp. |
Yung, Michael David
5 - Senior Officer of Issuer
Holder: 1072915 BC LTD (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$15,079
+301,587 vol $0.05 each |
301,587 | |
Filed 2016-05-09 Tx date 2016-04-18 |
$ATT
Abattis Bioceuticals Corp. |
Yung, Michael David
5 - Senior Officer of Issuer
Holder: 1072915 BC LTD (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-06 Tx date 2016-05-03 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,000
+100,000 vol $0.05 each |
200,000 | |
Filed 2016-05-06 Tx date 2016-05-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,250
+25,000 vol $0.05 each |
2,766,766 | |
Filed 2016-05-06 Tx date 2016-05-03 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,000
+200,000 vol $0.05 each |
250,000 | |
Filed 2016-05-06 Tx date 2014-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
Filed 2016-04-13 Tx date 2015-11-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,000
+100,000 vol $0.09 each |
100,000 | |
Filed 2016-04-13 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-04-13 Tx date 2015-11-02 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$4,500
+50,000 vol $0.09 each |
450,000 | |
Filed 2016-04-13 Tx date 2015-08-20 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,000
+300,000 vol $0.06 each |
400,000 | |
Filed 2016-04-13 Tx date 2014-09-17 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$33,000
+100,000 vol $0.33 each |
100,000 | |
Filed 2016-04-13 Tx date 2014-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Dancosse, Guy
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-04-08 Tx date 2016-04-08 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$165.00
+3,000 vol $0.055 each |
2,741,766 | |
Filed 2016-04-08 Tx date 2016-04-07 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,460
+172,000 vol $0.055 each |
2,738,766 | |
Filed 2016-04-05 Tx date 2016-04-01 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,500
+25,000 vol $0.06 each |
2,566,766 | |
Filed 2016-03-04 Tx date 2016-02-29 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
+25,000 vol |
2,541,766 | |
Filed 2015-11-12 Tx date 2015-08-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Holder: Manewagi Technologies Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$9,000
+100,000 vol $0.09 each |
100,000 | |
Filed 2015-11-12 Tx date 2014-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Holder: Manewagi Technologies Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-11-12 Tx date 2015-08-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$9,000
+100,000 vol $0.09 each |
||
Filed 2015-11-12 Tx date 2015-08-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$9,000
+100,000 vol $0.09 each |
||
Filed 2015-11-12 Tx date 2015-03-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$13,846
+76,923 vol $0.18 each |
76,923 | |
Filed 2015-11-12 Tx date 2014-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-11-12 Tx date 2015-08-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Holder: Manewagi Technologies Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$5,000
+100,000 vol $0.05 each |
100,000 | |
Filed 2015-11-12 Tx date 2014-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Holder: Manewagi Technologies Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-11-12 Tx date 2015-11-12 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$33,923
+376,923 vol $0.09 each |
376,923 | |
Filed 2015-11-12 Tx date 2015-11-09 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,153.84
-376,923 vol $0.08 each |
0 | |
Filed 2015-11-12 Tx date 2015-03-19 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$9,999
+76,923 vol $0.13 each |
376,923 | |
Filed 2015-08-25 Tx date 2015-08-24 |
$ATT
Abattis Bioceuticals Corp. |
Minshew, Brazos Arthur Glenn
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$30,000
+500,000 vol $0.06 each |
500,000 | |
Filed 2015-08-25 Tx date 2014-07-01 |
$ATT
Abattis Bioceuticals Corp. |
Minshew, Brazos Arthur Glenn
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-08-25 Tx date 2015-08-20 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$42,000
+700,000 vol $0.06 each |
700,000 | |
Filed 2015-08-25 Tx date 2014-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Fleming, William James
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-08-24 Tx date 2015-08-20 |
$ATT
Abattis Bioceuticals Corp. |
Sorocco, Douglas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,000
+300,000 vol $0.06 each |
675,000 | |
Filed 2015-08-24 Tx date 2015-08-20 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Options
50 - Grant of options
|
$42,000
+700,000 vol $0.06 each |
1,885,000 | |
Filed 2015-08-24 Tx date 2015-08-18 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,750
+25,000 vol $0.07 each |
2,516,766 | |
Filed 2015-07-20 Tx date 2015-07-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,893
+98,666 vol $0.08 each |
2,491,766 | |
Filed 2015-07-20 Tx date 2015-07-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$1,625
+25,000 vol $0.065 each |
2,393,100 | |
Filed 2015-07-20 Tx date 2015-06-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$2,750
+25,000 vol $0.11 each |
2,368,100 | |
Filed 2015-07-20 Tx date 2015-06-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$27,500
+250,000 vol $0.11 each |
||
Filed 2015-07-20 Tx date 2015-03-04 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$34,375
+196,429 vol $0.175 each |
2,172,985 | |
Filed 2015-07-20 Tx date 2015-05-06 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$14,000
+116,667 vol $0.12 each |
2,343,100 | |
Filed 2015-06-03 Tx date 2015-06-03 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$27,500
+250,000 vol $0.11 each |
2,280,004 |